Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Inogen (NASDAQ:INGN) on Thursday, setting a price target of $54, which is approximately 4.67% above the present share price of $51.59.
Antalffy expects Inogen to post earnings per share (EPS) of -$0.08 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Inogen, with an average price target of $57.
The analysts price targets range from a high of $60 to a low of $54.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $74.33 million and a net profit of -$1.97 million. The company's market cap is $1.14 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.6% and a 69.52% success rate.
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.